Pharmacopedia - User contributions [en]

Acetaminophen

2026-06-15T07:34:06Z

MDElliottMD: Acetaminophen safety depth (launch gate): Overdose+toxicity (Rumack-Matthew nomogram, NAC regimens) + Combination products/325mg FDA cap sections; template byte-preserved; multi-review-passed + mark-greenlit

{{MedTemplate
| generic = Acetaminophen (paracetamol, APAP)
| brand = Tylenol, Panadol (international), Ofirmev (IV); huge OTC presence
| structure =
| classes = [[:Category:Analgesics|Non-opioid analgesic]], [[:Category:Antipyretics|Antipyretic]]
| uses = <vote slug="mild-moderate-pain-use">Mild to moderate pain</vote>, <vote slug="fever-use">Fever</vote>, <vote slug="multimodal-analgesia-use">Multimodal post-surgical analgesia</vote>
| starting_dose = 325-1000 mg PO every 4-6 hours as needed; maximum 4 g/d in healthy adults, 3 g/d in regular users or hepatic risk; pediatric 10-15 mg/kg every 4-6 hours
| preparations = 325, 500, 650 mg tablets; 80, 160 mg chewables; 160 mg/5 mL pediatric liquid; 325 mg suppository; 1000 mg/100 mL IV (Ofirmev); fixed-dose combinations with opioids, decongestants, antihistamines
| fda_max = 4 g/d in healthy adults; 3 g/d conservative limit; 2 g/d in cirrhosis or chronic alcohol use
| pill_id =
| routes = Oral, rectal, IV
| onset = PO: 30-60 minutes; IV: minutes
| duration = 4-6 hours
| halflife = 1-3 hours (normal liver); markedly prolonged in overdose with glutathione depletion<ref name="tylenol-label">FDA OTC Monograph for acetaminophen-containing products, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021450s015lbl.pdf</ref>
| bioavailability = ~85-98% (oral)<ref name="tylenol-label" />
| pregnancy = Long the preferred analgesic-antipyretic in pregnancy; recent observational studies have raised speculative neurodevelopmental signals that remain under investigation.{{citation needed}}
| legal = OTC and [[USLegal:Prescription only|Rx-only]] (IV, combination products) in US
| mechanism = <vote slug="apap-mech-claim">Acetaminophen's analgesic and antipyretic actions are incompletely characterized; central COX inhibition (particularly the COX-2 splice variant sometimes called COX-3, and inhibition of arachidonic acid pathways in CNS at low peroxide concentrations) is the leading hypothesis, with possible contribution from descending serotonergic pathways and TRPV1 modulation by the AM404 metabolite.</vote> The absence of meaningful peripheral cyclooxygenase inhibition explains the lack of antiplatelet and anti-inflammatory effect compared with NSAIDs, and the gastroprotective profile. '''Dose-dependent hepatotoxicity''' via the CYP2E1 metabolite N-acetyl-p-benzoquinone imine (NAPQI) once glutathione is depleted; N-acetylcysteine is the antidote and is most effective within 8-10 hours of overdose<ref name="tylenol-label" />.
}}

== Overdose and toxicity ==
For a single acute ingestion at a known time, the Rumack-Matthew nomogram guides
whether to treat: a serum acetaminophen concentration is drawn no earlier than 4 hours
after ingestion and plotted against time.<ref>Rumack BH, Matthew H. Acetaminophen
poisoning and toxicity. Pediatrics. 1975;55(6):871-876.</ref> In the United States the
treatment line begins at 150 micrograms/mL at 4 hours (set 25% below Rumack and Matthew's
original 200 micrograms/mL line, the FDA-adopted treatment threshold); a level on or above the line
indicates N-acetylcysteine, a level below it does not.<ref>Wallace CI, Dargan PI, Jones
AL. Paracetamol overdose: an evidence based flowchart to guide management. Emerg Med J.
2002;19(3):202-205.</ref> The nomogram does NOT apply to chronic or repeated
(staggered) ingestion, an unknown ingestion time, levels drawn before 4 hours, or
modified/extended-release products; in those situations N-acetylcysteine is given
empirically with serial transaminase and acetaminophen monitoring.

Two established N-acetylcysteine regimens are used. The intravenous 21-hour (Prescott)
regimen gives 150 mg/kg as a loading dose, then 50 mg/kg over the next 4 hours, then
100 mg/kg over the following 16 hours.<ref>Prescott LF, Illingworth RN, Critchley JA, et
al. Intravenous N-acetylcysteine: the treatment of choice for paracetamol poisoning. Br
Med J. 1979;2(6198):1097-1100.</ref> The oral 72-hour regimen gives a 140 mg/kg loading
dose, then 70 mg/kg every 4 hours for 17 doses.<ref>Smilkstein MJ, Knapp GL, Kulig KW,
Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose.
N Engl J Med. 1988;319(24):1557-1562.</ref> Treatment is most effective when started
within 8 hours of ingestion, but is still given later, and in established liver injury or
acute liver failure, where it improves outcomes. Massive or late-presenting overdose may
require extended or increased dosing. This is reference information, not a treatment
protocol; overdose is a medical emergency managed by clinicians and poison control.

== Combination products and the 325 mg limit ==
Because acetaminophen is present in many products at once -- prescription opioid
combinations (e.g. hydrocodone/acetaminophen, oxycodone/acetaminophen) and over-the-
counter cold, flu, and sleep products -- people can exceed the maximum daily dose without
realizing it by stacking several acetaminophen-containing products, a leading route to
unintentional hepatotoxicity. In January 2011 the FDA acted on this risk for PRESCRIPTION
acetaminophen products: it asked manufacturers to limit acetaminophen to 325 mg per dosage
unit in prescription combination products (a change manufacturers completed by 2014), and it
required a boxed warning on all prescription products containing acetaminophen highlighting
the potential for severe liver injury.<ref>U.S. Food and Drug Administration. Drug Safety
Communication: Prescription acetaminophen products to be limited to 325 mg per dosage unit;
boxed warning will highlight potential for severe liver failure. January 13, 2011.</ref>
Over-the-counter acetaminophen products instead carry a Drug Facts "Liver warning," not a
boxed warning. Checking every product label for acetaminophen (sometimes abbreviated APAP)
and summing the total is the practical safeguard.

== References ==
<references />
[[Category:Analgesics]]
[[Category:Antipyretics]]

Template:MedTemplate

2026-06-14T21:33:10Z

MDElliottMD: Launch Gate 2: per-medicine disclaimer band (mark-approved)

<includeonly><div class="medpage"><div class="titleblock"><div class="tb-eyebrow">{{{classes|}}}</div><div class="tb-row"><div class="tb-name">{{{generic|{{PAGENAME}}}}}</div>{{#if:{{{brand|}}}|<div class="tb-brand">{{{brand}}}</div>}}</div></div>{{#cargo_store:_table=Medicines
| generic={{{generic|}}}
| brand={{{brand|}}}
| structure={{{structure|}}}
| classes={{{classes|}}}
| mechanism={{{mechanism|}}}
| uses={{{uses|}}}
| starting_dose={{{starting_dose|}}}
| preparations={{{preparations|}}}
| fda_max={{{fda_max|}}}
| pill_id={{{pill_id|}}}
| routes={{{routes|}}}
| onset={{{onset|}}}
| duration={{{duration|}}}
| halflife={{{halflife|}}}
| bioavailability={{{bioavailability|}}}
| pregnancy={{{pregnancy|}}}
| legal={{{legal|}}}
}}<div class="med-grid"><div class="med-main">{{#if:{{{intro|}}}|
{{{intro}}}
}}{{#if:{{{history|}}}|<div class="med-sec-head"><h2 class="sec-title" id="History">History</h2></div>
{{{history}}}}}<div class="med-sec-head"><h2 class="sec-title" id="Experience">Experience</h2></div>
<pharmaExperience/>
<div class="med-sec-head"><h2 class="sec-title" id="Problems">Problems</h2></div>
{{#if:{{{indications|}}}|{{{indications}}}|<p style="opacity:0.7; font-style:italic;">No problems yet. Be the first to suggest one.</p>}}

<span class="pcp-problem-suggest-wrap">[[Special:SuggestProblem/{{FULLPAGENAME}}|+ Add a problem]]</span><div class="med-sec-head"><h2 class="sec-title" id="Titration">Titration strategies</h2></div>
{{#if:{{{dosing|}}}|{{{dosing}}}|<p style="opacity:0.7; font-style:italic;">No titration strategies yet. Be the first to suggest one.</p>}}

<span class="pcp-titration-suggest-wrap">[[Special:SuggestTitration/{{FULLPAGENAME}}|+ Add a titration strategy]]</span>

<div class="med-sec-head"><h2 class="sec-title" id="Effects">Effects</h2></div>
{{#if:{{{effects|}}}{{{adverse|}}}|{{{effects|}}}{{#if:{{{adverse|}}}|

{{{adverse}}}}}|<p style="opacity:0.7; font-style:italic;">No effects listed yet. Be the first to suggest one.</p>}}

<span class="pcp-effect-suggest-wrap">[[Special:SuggestEffect/{{FULLPAGENAME}}|+ Add an effect]]</span>
{{#if:{{{pharmacokinetics|}}}{{{pk_absorption|}}}{{{pk_distribution|}}}{{{pk_metabolism|}}}{{{pk_elimination|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Pharmacokinetics">Pharmacokinetics</h2></div>
{{#if:{{{pk_absorption|}}}|<h3 class="med-subhead" id="Absorption">Absorption</h3>
{{{pk_absorption}}}
}}{{#if:{{{pk_distribution|}}}|<h3 class="med-subhead" id="Distribution">Distribution</h3>
{{{pk_distribution}}}
}}{{#if:{{{pk_metabolism|}}}|<h3 class="med-subhead" id="Metabolism">Metabolism</h3>
{{{pk_metabolism}}}
}}{{#if:{{{pk_elimination|}}}|<h3 class="med-subhead" id="Elimination">Elimination</h3>
{{{pk_elimination}}}
}}{{#if:{{{pharmacokinetics|}}}|
{{{pharmacokinetics}}}}}
}}{{#if:{{{pharmacodynamics|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Pharmacodynamics">Pharmacodynamics</h2></div>
{{{pharmacodynamics}}}}}{{#if:{{{interactions|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Interactions">Interactions</h2></div>
{{{interactions}}}}}{{#if:{{{pregnancy_details|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Pregnancy">Pregnancy and lactation</h2></div>
{{{pregnancy_details}}}}}{{#if:{{{monitoring|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Monitoring">Monitoring</h2></div>
{{{monitoring}}}}}{{#if:{{{counseling|}}}|<div class="med-sec-head"><h2 class="sec-title" id="Counseling">Patient counseling</h2></div>
{{{counseling}}}}}<div class="med-sec-head"><h2 class="sec-title" id="Anecdote">Relevant anecdote</h2></div>
{{#if:{{{anecdotes|}}}|{{{anecdotes}}}|<p style="opacity:0.7; font-style:italic;">No anecdotes yet. Share a relevant one.</p>}}

<span class="pcp-anecdote-suggest-wrap">[[Special:SuggestAnecdote/{{FULLPAGENAME}}|+ Add an anecdote]]</span>
<div class="med-sec-head"><h2 class="sec-title" id="Literature">Relevant Literature</h2></div>
<pharmaLiterature/>
{{#if:{{{seealso|}}}|<div class="med-sec-head"><h2 class="sec-title" id="SeeAlso">See also</h2></div>
{{{seealso}}}}}{{#if:{{{references|}}}|<div class="med-sec-head"><h2 class="sec-title" id="References">References</h2></div>
{{{references}}}}}</div><div class="med-rail"><div class="med-rail-inner"><div class="med-channel ch-pharmacy"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacy</span></div>{{#if:{{{starting_dose|}}}|<div class="med-field"><div class="fl">Starting dose</div><div class="fv">{{{starting_dose}}}</div></div>}}{{#if:{{{preparations|}}}|<div class="med-field"><div class="fl">Preparations</div><div class="fv">{{{preparations}}}</div></div>}}{{#if:{{{fda_max|}}}|<div class="med-field"><div class="fl">US FDA Max</div><div class="fv">{{{fda_max}}}</div></div>}}{{#if:{{{pill_id|}}}|<div class="med-field"><div class="fl">Pill ID</div><div class="fv"><div class="pcp-pill-id"><div class="mw-collapsible mw-collapsed" data-expandtext="Show pill identifiers" data-collapsetext="Hide pill identifiers">
{{{pill_id}}}
</div></div></div></div>}}</div><div class="med-channel ch-uses"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Common uses</span></div><pharmaCommonUses>{{{uses|}}}</pharmaCommonUses></div>{{#if:{{{structure|}}}|<div class="med-channel ch-structure"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Structure</span></div><div class="med-structure">[[File:{{{structure}}}|frameless|{{{structuresize|240px}}}|alt=Structure of {{{generic|{{PAGENAME}}}}}]]</div></div>}}<div class="med-channel ch-classes"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Classification(s)</span></div>{{#if:{{{classes|}}}|<div class="med-field"><div class="fl">Classes</div><div class="fv">{{{classes}}}</div></div>}}</div><div class="med-channel ch-pharmacology"><div class="ch-head"><span class="ch-mark"></span><span class="ch-name">Pharmacology</span></div>{{#if:{{{routes|}}}|<div class="med-field"><div class="fl">Routes</div><div class="fv">{{{routes}}}</div></div>}}{{#if:{{{onset|}}}|<div class="med-field"><div class="fl">Onset</div><div class="fv">{{{onset}}}</div></div>}}{{#if:{{{duration|}}}|<div class="med-field"><div class="fl">Duration</div><div class="fv">{{{duration}}}</div></div>}}{{#if:{{{halflife|}}}|<div class="med-field"><div class="fl">Half-life</div><div class="fv">{{{halflife}}}</div></div>}}{{#if:{{{bioavailability|}}}|<div class="med-field"><div class="fl">Bioavailability</div><div class="fv">{{{bioavailability}}}</div></div>}}{{#if:{{{pregnancy|}}}|<div class="med-field"><div class="fl">Pregnancy</div><div class="fv">{{{pregnancy}}}</div></div>}}{{#if:{{{legal|}}}|<div class="med-field"><div class="fl">Legal status</div><div class="fv">{{{legal}}}</div></div>}}{{#if:{{{mechanism|}}}|<div class="med-field"><div class="fl">Purported mechanism</div><div class="fv">{{{mechanism}}}</div></div>}}</div></div></div></div><div class="med-disclaimer">Pharmacopedia is intended for reference. Nothing here is advice. In an emergency call 911; US Poison Control 1-800-222-1222. See the [[Pharmacopedia:General disclaimer|full disclaimer]].</div>[[Category:Medicines]]</div></includeonly><noinclude>
{{#cargo_declare:_table=Medicines
| generic=String
| brand=String
| structure=File
| classes=List (,) of String
| mechanism=String
| uses=String
| starting_dose=String
| preparations=String
| fda_max=String
| pill_id=Text
| routes=List (,) of String
| onset=String
| duration=String
| halflife=String
| bioavailability=String
| pregnancy=String
| legal=String
}}

== Usage ==

Medicine entry template. Fill in fields below; empty fields are auto-omitted.

The <code>problems</code> parameter still uses the historical name in template wikitext to preserve compatibility with every existing medicine page; the rendered H2 heading on the page now reads "Problems" (see [[Special:Problems]] for the repository and [[Pharmacopedia:Citation needed]] adjacent context).

<pre>
{{MedTemplate
| generic =
| brand =
| structure =
| classes =
| uses =
| starting_dose =
| preparations =
| fda_max =
| pill_id =
| routes =
| onset =
| duration =
| halflife =
| bioavailability =
| pregnancy =
| legal =
| mechanism =
| intro =
| history =
| indications =
| dosing =
| effects =
| pk_absorption =
| pk_distribution =
| pk_metabolism =
| pk_elimination =
| pharmacodynamics =
| interactions =
| pregnancy_details =
| monitoring =
| counseling =
| anecdotes =
| seealso =
| references =
}}
</pre>

Notes:
* ''The'' <code>problems</code> ''parameter feeds the "Problems" H2 section on the rendered page. Content typically consists of'' <code><problem ref="..."/></code> ''tags (formerly'' <code><problem ref="..."/></code>'').'' ''Use'' <code>[[Special:SuggestProblem|SuggestProblem]]</code> ''or the per-page'' <code>+ Add a problem</code> ''link to propose new entries.''
* ''The'' <code>adverse</code> ''parameter is deprecated; its content is still rendered, but new pages should combine therapeutic and adverse effects into the single'' <code>effects</code> ''parameter.''
* ''The'' <code>formula</code> ''parameter is deprecated and no longer rendered. It can be removed from existing pages.''
* ''The single'' <code>pharmacokinetics</code> ''parameter is deprecated; new pages should use'' <code>pk_absorption</code>'','' <code>pk_distribution</code>'','' <code>pk_metabolism</code>'', and'' <code>pk_elimination</code>''.''

This template also populates the '''Medicines''' Cargo table. See [[Special:CargoTables/Medicines]].

[[Category:Templates]]
</noinclude>

Pharmacopedia:General disclaimer

2026-06-14T21:32:24Z

MDElliottMD: Launch Gate 2: medical disclaimer page (fixes footer 404; mark-approved)

__NOTOC__
'''Pharmacopedia is intended for reference. Nothing here is advice.'''

If you're looking for advice, please speak to a clinician directly. Nothing here can replace a clinician's expertise. If you have a medical question or emergency, consult a licensed clinician or call emergency services. For overdose or poisoning in the United States, call Poison Control at 1-800-222-1222.

This disclaimer applies to every page on Pharmacopedia.

Warfarin

2026-06-13T18:04:49Z

MDElliottMD: B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

{{MedTemplate
| generic = Warfarin
| brand = Coumadin (discontinued in US but name in common use), Jantoven
| structure =
| classes = [[:Category:Anticoagulants|Anticoagulant]], [[:Category:Vitamin_K_antagonists|Vitamin K antagonist]]
| uses = <vote slug="mechanical-heart-valve-use">Mechanical heart valves</vote>, <vote slug="aps-use">Antiphospholipid syndrome thromboprophylaxis</vote>, <vote slug="aaf-stroke-prevention-valve-use">Atrial fibrillation with mitral stenosis or mechanical valves</vote>, <vote slug="vte-treatment-use">VTE treatment and secondary prevention</vote>, <vote slug="ckd5-vte-use">VTE in advanced CKD (DOACs less established)</vote>
| starting_dose = Typical 5 mg PO daily; 2.5 mg in elderly, low body weight, malnutrition, hepatic dysfunction. Genotype-guided initial dosing per CPIC/IWPC algorithms (CYP2C9, VKORC1, CYP4F2) is one of the most-established PGx applications in current practice
| preparations = 1, 2, 2.5, 3, 4, 5, 6, 7.5, 10 mg tablets (color-coded by strength)
| fda_max = No fixed maximum; titrated to INR target
| pill_id =
| routes = Oral, IV (rarely used; same dose)
| onset = Anticoagulant effect at 24-72 hours; full INR effect 5-7 days
| duration = 2-5 days after stopping (factor II resynthesis-limited)
| halflife = 36-42 hours (R/S enantiomers differ; S-warfarin is 2-5× more potent and cleared by CYP2C9)<ref name="coumadin-label">FDA Prescribing Information, Coumadin (warfarin sodium), Bristol-Myers Squibb, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s108lbl.pdf</ref>
| bioavailability = ~100% (oral)<ref name="coumadin-label" />
| pregnancy = '''Contraindicated in pregnancy''' (warfarin embryopathy, fetal hemorrhage) except in mechanical mitral valves where the maternal mortality of alternative agents may exceed fetal risk.<ref name="coumadin-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="warfarin-mech-claim">Warfarin inhibits vitamin K epoxide reductase complex 1 (VKORC1), preventing regeneration of reduced vitamin K and γ-carboxylation of glutamate residues on factors II, VII, IX, X, and proteins C and S; the result is hypofunctional clotting factors, the most clinically important being factor II (prothrombin, half-life ~60 hours) whose depletion drives the steady-state anticoagulant effect.</vote> CYP2C9 (S-warfarin clearance) and VKORC1 (drug target) polymorphisms together explain 30-50% of inter-individual dosing variance and are the prototype pharmacogenomic target in clinical use<ref name="cpic-warfarin">CPIC Guideline for CYP2C9, VKORC1, CYP4F2, and Warfarin, 2017. https://cpicpgx.org/guidelines/guideline-for-warfarin-and-cyp2c9-and-vkorc1/</ref>. Reversal: vitamin K, 4F-PCC for life-threatening bleeding (FFP if PCC unavailable).
}}

== References ==
<references />
[[Category:Anticoagulants]]
[[Category:Vitamin K antagonists]]

Desiccated thyroid

2026-06-13T18:04:47Z

MDElliottMD: B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

Desiccated thyroid (also called natural thyroid, thyroid extract, or by the historical brand Armour Thyroid) is porcine thyroid gland, defatted and powdered, containing both thyroxine (T4) and triiodothyronine (T3) in a fixed ratio of roughly 4:1 by weight as required by the United States Pharmacopeia<ref name="armour-label">FDA Prescribing Information, Armour Thyroid (thyroid tablets, USP), Allergan, current revision. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=003444</ref>. It was introduced in 1892 by George Murray and has been continuously prescribed since, predating both the isolation of thyroxine (1914) and the synthetic levothyroxine of the 1950s. Modern endocrinology guidelines prefer synthetic [[Levothyroxine]] as first-line replacement, but a residual population of patients and clinicians prefer desiccated thyroid for its T3 content and historical track record.

{{MedTemplate
| generic = Thyroid (desiccated)
| brand = Armour Thyroid, NP Thyroid, Nature-Throid, WP Thyroid
| structure =
| classes = [[:Category:Thyroid_hormones|Thyroid hormone]], [[:Category:Hormone_replacement|Hormone replacement]]
| uses = <vote slug="hypothyroidism-use">Hypothyroidism</vote>, <vote slug="goiter-use">Goiter</vote>
| starting_dose = 30 mg PO daily (1/2 grain); titrate by TSH at 6-8 weeks; 60 mg desiccated thyroid is approximately equivalent to 88-100 mcg levothyroxine
| preparations = 15, 30, 60, 90, 120, 180, 240, 300 mg tablets (1/4 to 5 grains; 1 grain = 60 mg)
| fda_max = No fixed maximum; titrated to TSH target
| pill_id =
| routes = Oral
| onset = TSH normalization 4-8 weeks
| duration = Steady-state at 4-6 weeks
| halflife = T4 ~7 days; T3 ~1 day<ref name="armour-label" />
| bioavailability = Variable; reduced by food, calcium, iron, PPIs<ref name="armour-label" />
| pregnancy = Synthetic levothyroxine is the standard-of-care in pregnancy; desiccated thyroid use in pregnancy is not well studied.<ref name="ata2017-preg">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. PMID 28056690.</ref>
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="desiccated-thyroid-mech-claim">Desiccated thyroid supplies both T4 and T3 in a roughly 4:1 ratio; T4 is peripherally deiodinated to T3, but exogenous T3 supplementation produces faster onset and supraphysiologic post-dose peaks that synthetic T4 monotherapy avoids.</vote> Brand-to-brand and lot-to-lot variability in T3:T4 ratio is greater than with synthetic levothyroxine, which is why endocrine guidelines prefer the synthetic<ref name="armour-label" />.
}}

== References ==
<references />

Liothyronine

2026-06-13T18:04:45Z

MDElliottMD: B3 citation patch (home-claude, PM-approved): clear [citation needed] with verified ref

{{MedTemplate
| generic = Liothyronine (T3, triiodothyronine sodium)
| brand = Cytomel (oral), Triostat (IV)
| structure =
| classes = [[:Category:Thyroid_hormones|Thyroid hormone]], [[:Category:Hormone_replacement|Hormone replacement]]
| uses = <vote slug="hypothyroidism-T3-adjunct-use">Hypothyroidism (T3 supplement, selected refractory cases)</vote>, <vote slug="myxedema-coma-use">Myxedema coma (IV, in addition to T4)</vote>, <vote slug="thyroid-cancer-tsh-suppression-bridge-use">Bridge between T4 withdrawal and radioiodine scan/treatment in thyroid cancer</vote>
| starting_dose = Hypothyroidism: 5-25 mcg PO daily (start low, titrate slowly); myxedema coma: 5-20 mcg IV q4-12h with T4 loading
| preparations = 5, 25, 50 mcg tablets (Cytomel); 10 mcg/mL IV (Triostat)
| fda_max = 100 mcg/d typical
| pill_id =
| routes = Oral, IV
| onset = Hours (faster than T4); peak biologic activity 24-48 hours
| duration = 24-72 hours
| halflife = ~1 day (much shorter than T4's ~7 days)<ref name="cytomel-label">FDA Prescribing Information, Cytomel (liothyronine sodium), Pfizer/King, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010379s055lbl.pdf</ref>
| bioavailability = ~95% (oral)<ref name="cytomel-label" />
| pregnancy = T4 (levothyroxine) is the first-line in pregnancy; T3 is rarely needed.<ref name="ata2017-preg">Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017;27(3):315-389. PMID 28056690.</ref>
| legal = [[USLegal:Prescription only|Rx-only]] in US
| mechanism = <vote slug="liothyronine-mech-claim">Liothyronine is bioidentical T3 (triiodothyronine), the active thyroid hormone that binds nuclear thyroid hormone receptors with ~10× the affinity of T4; T4 (levothyroxine) is essentially a prodrug peripherally deiodinated to T3.</vote> Direct T3 supplementation bypasses peripheral deiodination, useful in myxedema coma (rapid clinical effect needed) and in some refractory hypothyroidism (combination T4+T3, controversial). Short half-life produces fluctuating serum levels with intermittent supraphysiologic peaks — one reason T4 monotherapy remains the practical standard<ref name="cytomel-label" />.
}}

== References ==
<references />
[[Category:Thyroid hormones]]
[[Category:Hormone replacement]]

Problem:Weight loss

2026-06-13T06:05:32Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Intentional weight reduction (overlaps with obesity but covers users without that diagnosis).

== Medicines used for Weight loss ==

<problemMedicines slug="weight-loss" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Vomiting

2026-06-13T06:05:30Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Forceful expulsion of gastric contents.

== Medicines used for Vomiting ==

<problemMedicines slug="vomiting" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Vertigo

2026-06-13T06:05:28Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Illusory sensation of self or environmental motion.

== Medicines used for Vertigo ==

<problemMedicines slug="vertigo" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:VTE prevention or treatment

2026-06-13T06:05:27Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Prevention or treatment of venous thromboembolism (DVT/PE).

== Medicines used for VTE prevention or treatment ==

<problemMedicines slug="anticoagulation-vte" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Type 2 diabetes mellitus

2026-06-13T06:05:25Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Diabetes mellitus, type 2 — insulin resistance with relative insulin deficiency.

== Medicines used for Type 2 diabetes mellitus ==

<problemMedicines slug="diabetes-type-2" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Type 2 Diabetes Mellitus

2026-06-13T06:05:23Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Type 2 Diabetes Mellitus ==

<problemMedicines slug="type-2-diabetes-mellitus" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Type 1 Diabetes Mellitus

2026-06-13T06:05:21Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Type 1 Diabetes Mellitus ==

<problemMedicines slug="type-1-diabetes-mellitus" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Trichotillomania

2026-06-13T06:05:19Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Trichotillomania ==

<problemMedicines slug="trichotillomania" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Treatment-resistant depression (augmentation)

2026-06-13T06:05:17Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Treatment-resistant depression (augmentation) ==

<problemMedicines slug="trd-augment" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Treatment-Resistant Depression

2026-06-13T06:05:16Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

A major depressive episode that has not responded adequately to two or more adequate trials of antidepressant medicines.

== Medicines used for Treatment-Resistant Depression ==

<problemMedicines slug="treatment-resistant-depression" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Traumatic Brain Injury

2026-06-13T06:05:13Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Traumatic Brain Injury ==

<problemMedicines slug="traumatic-brain-injury" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Tourette Syndrome

2026-06-13T06:05:12Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Tourette Syndrome ==

<problemMedicines slug="tourette-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Tobacco Use Disorder

2026-06-13T06:05:10Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

A problematic pattern of tobacco use leading to clinically significant impairment or distress.

== Medicines used for Tobacco Use Disorder ==

<problemMedicines slug="tobacco-use-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Tension-type headache

2026-06-13T06:05:08Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Bilateral pressing/tightening headache, mild–moderate intensity.

== Medicines used for Tension-type headache ==

<problemMedicines slug="tension-headache" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Stimulant Use Disorder

2026-06-13T06:05:06Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Stimulant Use Disorder ==

<problemMedicines slug="stimulant-use-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Specific Learning Disorder with Dyslexia

2026-06-13T06:05:04Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Specific Learning Disorder with Dyslexia ==

<problemMedicines slug="specific-learning-disorder-with-dyslexia" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Specific Learning Disorder with Dyscalculia

2026-06-13T06:05:02Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Specific Learning Disorder with Dyscalculia ==

<problemMedicines slug="specific-learning-disorder-with-dyscalculia" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Social anxiety disorder

2026-06-13T06:05:01Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Social anxiety disorder ==

<problemMedicines slug="social-anxiety" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Social Anxiety Disorder

2026-06-13T06:04:59Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Social Anxiety Disorder ==

<problemMedicines slug="social-anxiety-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Smoking cessation

2026-06-13T06:04:57Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Tobacco/nicotine cessation pharmacotherapy.

== Medicines used for Smoking cessation ==

<problemMedicines slug="smoking-cessation" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Sensory Processing Sensitivity

2026-06-13T06:04:55Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Sensory Processing Sensitivity ==

<problemMedicines slug="sensory-processing-sensitivity" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Sensory Processing Disorder

2026-06-13T06:04:53Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Sensory Processing Disorder ==

<problemMedicines slug="sensory-processing-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Seasonal Affective Disorder

2026-06-13T06:04:52Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Seasonal Affective Disorder ==

<problemMedicines slug="seasonal-affective-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizotypal Personality Disorder

2026-06-13T06:04:50Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizotypal Personality Disorder ==

<problemMedicines slug="schizotypal-personality-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizophrenia

2026-06-13T06:04:49Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizophrenia ==

<problemMedicines slug="schizophrenia" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizoid Personality Disorder

2026-06-13T06:04:47Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizoid Personality Disorder ==

<problemMedicines slug="schizoid-personality-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Schizoaffective Disorder

2026-06-13T06:04:46Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Schizoaffective Disorder ==

<problemMedicines slug="schizoaffective-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Rosacea

2026-06-13T06:04:44Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Chronic facial erythema and telangiectasias, sometimes papulopustular.

== Medicines used for Rosacea ==

<problemMedicines slug="rosacea" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Rheumatoid Arthritis

2026-06-13T06:04:42Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Rheumatoid Arthritis ==

<problemMedicines slug="rheumatoid-arthritis" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Restless Legs Syndrome

2026-06-13T06:04:40Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Restless Legs Syndrome ==

<problemMedicines slug="restless-legs-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Rejection Sensitivity Dysphoria

2026-06-13T06:04:38Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Rejection Sensitivity Dysphoria ==

<problemMedicines slug="rejection-sensitivity-dysphoria" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Recreational use

2026-06-13T06:04:37Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Use of a medicine outside an approved medical indication for its subjective effects. Documented here as a real use category, without endorsement.

== Medicines used for Recreational use ==

<problemMedicines slug="recreational-use" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Public speaking anxiety

2026-06-13T06:04:35Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Situational anxiety around public speaking or performance.

== Medicines used for Public speaking anxiety ==

<problemMedicines slug="public-speaking" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Psoriatic Arthritis

2026-06-13T06:04:33Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Psoriatic Arthritis ==

<problemMedicines slug="psoriatic-arthritis" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Psoriasis

2026-06-13T06:04:32Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Chronic immune-mediated scaling skin disease.

== Medicines used for Psoriasis ==

<problemMedicines slug="psoriasis" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Pruritus

2026-06-13T06:04:30Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Itching, generalized or localized.

== Medicines used for Pruritus ==

<problemMedicines slug="itch" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Premenstrual Dysphoric Disorder

2026-06-13T06:04:28Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Premenstrual Dysphoric Disorder ==

<problemMedicines slug="premenstrual-dysphoric-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Premature ejaculation

2026-06-13T06:04:26Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Premature ejaculation ==

<problemMedicines slug="premature-ejaculation" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Postural Orthostatic Tachycardia Syndrome

2026-06-13T06:04:25Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Postural Orthostatic Tachycardia Syndrome ==

<problemMedicines slug="postural-orthostatic-tachycardia-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Posttraumatic Stress Disorder

2026-06-13T06:04:23Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Posttraumatic Stress Disorder ==

<problemMedicines slug="posttraumatic-stress-disorder" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Polycystic Ovary Syndrome

2026-06-13T06:04:21Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Polycystic Ovary Syndrome ==

<problemMedicines slug="polycystic-ovary-syndrome" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Persistent Depressive Disorder (Dysthymia)

2026-06-13T06:04:19Z

MDElliottMD: Launch A7: honest early-note + noindex placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>
__NOINDEX__

== Medicines used for Persistent Depressive Disorder (Dysthymia) ==

<problemMedicines slug="persistent-depressive-disorder-dysthymia" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Peptic ulcer disease

2026-06-13T06:04:18Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Ulceration of gastric or duodenal mucosa.

== Medicines used for Peptic ulcer disease ==

<problemMedicines slug="peptic-ulcer" />

[[Category:Problems]]
[[Category:Problem stubs]]

Problem:Parkinson disease

2026-06-13T06:04:16Z

MDElliottMD: Launch A7: honest early-note placeholder (mark-tapped)

<span class="pcp-early-note">This page is early; a full clinical description is coming. The cross-linked medicines below are live.</span>

Progressive degeneration of dopaminergic neurons in the substantia nigra.

== Medicines used for Parkinson disease ==

<problemMedicines slug="parkinson-disease" />

[[Category:Problems]]
[[Category:Problem stubs]]